Related Experiment Video
Updated: Mar 27, 2026
Enrichment of Bruch's Membrane from Human Donor Eyes
Published on: November 15, 2015
Age-related macular degeneration: Complement in action
Menno van Lookeren Campagne1, Erich C Strauss2, Brian L Yaspan3
1Department of Immunology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, United States.
Insights
Genetic factors influencing the complement system, specifically complement factor H (CFH) and complement factor I (CFI), are linked to Age-Related Macular Degeneration (AMD). This review explores AMD genetics, complement dysregulation, and new therapies.
Area of Science:
- Immunology
- Genetics
- Ophthalmology
Background:
- The complement system is crucial for host defense but requires strict regulation to prevent tissue damage.
- Polymorphisms in complement factor H (CFH) and complement factor I (CFI) genes are associated with Age-Related Macular Degeneration (AMD) risk.
- AMD is a primary cause of vision loss in the elderly population.
Purpose of the Study:
- To review the genetic underpinnings of AMD.
- To examine the role of complement dysregulation in AMD pathogenesis.
- To highlight emerging therapeutic strategies targeting complement activation in AMD.
Main Methods:
- Literature review focusing on genetic associations with AMD.
- Analysis of the role of complement regulatory proteins (CFH, CFI) in disease.
- Synthesis of current research on complement-targeted AMD therapies.
Main Results:
- Specific genetic variations in CFH and CFI significantly increase AMD susceptibility.
- Dysregulation of the alternative complement pathway is implicated in AMD development.
- Therapeutic strategies aim to modulate complement activation for AMD treatment.
Conclusions:
- Genetic variations in complement regulators are key risk factors for AMD.
- Controlling complement system overactivation presents a promising therapeutic avenue for AMD.
- Further research into complement pathways could lead to novel treatments for vision impairment.
Abstract:
The complement system plays a key role in host-defense against common pathogens but must be tightly controlled to avoid inflammation and tissue damage. Polymorphisms in genes encoding two important negative regulators of the alternative complement pathway, complement factor H (CFH) and complement factor I (CFI), are associated with the risk for Age-Related Macular Degeneration (AMD), a leading cause of vision impairment in the ageing population. In this review, we will discuss the genetic basis of AMD and the potential impact of complement de-regulation on disease pathogenesis. Finally, we will highlight recent therapeutic approaches aimed at controlling complement activation in patients with AMD.
